|
Friday June 5 |
| 09:00-09:45 |
Registration and coffee |
| 09:45-10:00 |
Welcome and Introduction |
|
|
|
Morning program |
|
Chair: Jon Wakefield |
| 10:00-10:20 |
Jon Wakefield |
Bayesian individualization via sampling-based methods |
| 10:20-10:40 |
J Bennett, L Lacey, K Koch, A Bye |
Determination of the population pharmacokinetics of bismuth from GR122311X in healthy volunteers using the gibbs sampler bayesian method |
| 10:40-11:00 |
L Harnisch, W Weber |
Population approach to nonlinear pharmacokinetics of a new drug under development |
| 11:00-11:20 |
NJ Bruce, AH Thomson, HL Elliott |
Population pharmacokinetics of tacrolimus in liver transplant patients |
| 11:20-11:40 |
M Karlsson, P Milligan, D Nichols |
Determination of relative potency for drug and metabolite in vivo |
| 11:40-12:00 |
N Jonsson, JR Wade, G Almqvist, M Karlsson |
Discrimination between rival dosing histories |
| 12:00-13:45 |
Lunch |
|
Afternoon program |
PK/PD |
Chair: Leon Aarons: |
| 13:45-14:10 |
D Hille, R Bruno, S Durrleman, LB Sheiner |
Relationship between the pharmacokinetics and the pharmacodynamics of taxotere in cancer patients |
| 14:10-14:35 |
K Fattinger, D Verotta, HC Porchet, A Munafo, J-Y le Cotonnec, LB Sheiner |
Pharmacokinetic/-dynamic modeling of a bivariate control system: luteinizing hormone and testosterone response to GnRH antagonist antide |
| 14:35-14:55 |
C Laveille, N Frey, G Lerebours, G Resplandy, R Jochemsen |
Population pharmacokinetic-pharmacodynamic of a new specific bradycardic agent: S-16257 |
| 14:55-15:15 |
S Marshall, HL Elliott, PA Meredith |
Prediction of simvastatin pharmacological response: a population analysis |
| 15:15-15:45 |
Coffee break |
|
Afternoon session II |
Population Toxicokinetics and Scaling from animal to man |
Chair: Eliane Fuseau |
| 15:45-16:05 |
P Burtin, J van Bree, F Mentre, S Hensel, JL Steimer |
A prospective evaluation of sparse sampling for toxicokinetics in the course of drug development |
| 16:05-16:25 |
V Cosson, E Fuseau, C Efthymiopoulos, A Bye |
From animal to man |
| 16:25-16:45 |
W Weber, L Harnisch, M Zimmer, P Crause, B Katgely |
Optimization of a ''first dose in man study'' using a NONMEM model for mammals |
| 16:45 - 17:30 |
Discussions and questions |
|
Chair: Lutz Harnisch |
| 16:45-17:00 |
F Keller, D Zellner, T Frankewitsch, M Giehl |
Population kinetics and individual drug dosage adjustment |
|
| 17:30-18:30 |
Poster session I, Software demonstrations |
| |
|
|
|
| 20:00-24:00 |
Social Evening |
|
|
|
|
|
Saturday June 10 |
|
Tutorial I |
|
Chair: France Mentré |
| 09:30-09:45 |
H Hassani |
Stochastic model in the analysis of migraine data |
| 09:45-10:30 |
F Rombout |
An industrial perspective: practical stages in model development |
| 10:30-11:00 |
Coffee break |
|
Tutorial II |
|
Chair: Gudrun Wallenstein |
| 11:00-11:45 |
L Aarons |
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies |
| |
| 11:45-12:00 |
H-J Röthig, W Weber |
Closing remarks |
| 12:00-14:00 |
Poster session II, software demonstrations |
Posters Friday (group I)
Study design
1. D Breilh, C Pobel, MC Saux Non linear pharmacokinetics of ethanol Analysis of patients with NONMEM. study I
2. D Breilh, C Pobel, MC Saux Non linear pharmacokinetics of ethanol Population model with NONMEM after an optimal sampling duration. study II
3. B Charpiat, V Broant, G Tissier, JM Sab, P Maire, RW Jelliffe How many patients and blood levels for population pharmacokinetic analysis? a study with a one compartment model
4. AC Falcao, MM Fernandez de Gatta, A Dominguez-Gil, JM Lanao Sampling strategies for population analysis: a theoretical study to support practical results obtained with caffeine in premature neonates
5. NS Houwing, F Rombout Population pharmacokinetics: effect of sampling scheme on parameter estimation
Drug development
6. G Lockwood, G Maier The use of population pharmacokinetic approaches to aid in the assessment of bioequivalence for a highly variable drug
7. M Looby, U Wuenscher, M Weiss NONMEM in destructive sampling experiments: experiences with the toxicokinetics of dibromchloromethane
8. F Mesnil, F Mentre, C Dubruc, A Mallet Population pharmacokinetics analysis of mizolastine: estimation with NPML and validation
9. P Milligan, M Karlsson, D Nichols High variability compounds - high risk for developers?
10. JPR Monteleone, NHG Holford Modeling interoccasion variability in toxicokinetics and toxicodynamics
Data rich situations
11. R Schoemaker, A Cohen Estimation of kinetic/dynamic curves with insufficient information for each individual using non-linear mixed effect modelling
12. J Wade, B-M Emanuelsson, LL Gustafsson, M Karlsson A population approach enables the characterisation of saturable protein binding for Ropivacaine
13. W Weber, L Harnisch, M Zimmer, C Rokitta, P Mendes New evidence for a triexponential disposition of Cefotaxim
Software demonstrations
1. M Tod An algorithm for the estimation of optimal sampling times in pharmacokinetics by the ed, eid and api criteria
2. S Urien MP2 (Micropharm population): a Windows application for population pharmacokinetics
3. J Wakefield, G Strehlau Software product POPKAN; population pharmacokinetic modelling and analysis
Posters Saturday (group II)
PK/PD
14. D Breilh, C Pobel, C Roth, MC Saux, G Janvier Sufentanyl Pharmacokinetic-pharmacodynamic modeling (PK/PD) on NONMEM in 10 patients with coronary surgery
15. MJ du Preez, JH Botha, ML McFadyen, M Adhikari Effect concentration relationships of theophylline in apnoea of prematurity
16. S Rietbrock, S Harder, H Baas Influence of apomorphine on the PK/PD-relationship of levodopa: two-step versus NONMEM analysis
TDM
17. D Breilh, C Pobel, P Rispal, MC Saux Population of vancomycine with continuous infusion administered in neutropenic patients modeling on NPEEM2-NONMEM-P-PHARM
18. J Bres, D Cupissol, J Nouguier-Soule, C Gestin-Boyer, Ü Büttner, B Palomba Population distribution of platinum pharmacokinetic parameters for dosage recommendations of CDDP and adaptive control during the course of therapy, using different softwares
19. MT Mateu-Garcia, JJ Porez-Ruixo, VG Casabo-Alos, NV Jimenez-Torres Apache II as predictor of gentamicin pharmacokinetic parameters in critical ill patients
20. H Peyriere, J Bres, D Hillaire-Buys Performance evaluation of three softwares for bayesian predictions of teicoplanin pharmacokinetic parameters: Apis Micropharm, PKS Abbott
21. D Santos Buelga, MF Delgado Iribarnegaray, MJ Garca, MJ Otero, A Falcao, A Dominguez-Gil Carbamazepine population pharmacokinetics in children
22. M Tod, C Padoin, C Minozzi, J Cougnard, O Petitjean A population pharmacokinetic study of isepamicin in ICU patients
Oncology
23. LS Murray, DI Jodrell, JG Morrison, AW Kelman, DJ Kerr, B Whiting, SB Kaye A population approach to predicting post-treatment levels of epirubicin in patients with advanced breast cancer
24. M Sandström, A Freijs, R Larsson, P Nygren, J Bergh, M-L Fjollskog, M Karlsson Lack of relationship between systemic exposure for the component drugs of the FEC regimen in breast cancer patients
24. B Tranchand, S Urien, CJ Ardiet Population pharmacokinetics of intravenous melphalan: NONMEM and MP2 analysis
